Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Quality Improvements of Veterans Health Administration Radiation Oncology Services Through Partnership for Accreditation With the ACR.

Kapoor R, Moghanaki D, Rexrode S, Monzon B, Ray M, Hulick PR, Albuquerque K, Rosenthal SA, Palta JR, Hagan MP.

J Am Coll Radiol. 2018 Dec;15(12):1732-1737. doi: 10.1016/j.jacr.2018.06.029. Epub 2018 Aug 9.

PMID:
30100162
2.

Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy.

Serrano N, Moghanaki D, Asher D, Karlin J, Schutzer M, Chang M, Hagan MP.

Brachytherapy. 2016 Jul-Aug;15(4):435-441. doi: 10.1016/j.brachy.2016.04.002. Epub 2016 May 12.

PMID:
27180124
3.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL.

J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814.

4.

Availability of single-fraction palliative radiotherapy for cancer patients receiving end-of-life care within the Veterans Healthcare Administration.

Moghanaki D, Cheuk AV, Fosmire H, Anscher MS, Lutz ST, Hagan MP, Dawson GA; U.S. Veterans Healthcare Administration National Palliative Radiotherapy Taskforce.

J Palliat Med. 2014 Nov;17(11):1221-5. doi: 10.1089/jpm.2014.0041. Epub 2014 Sep 4.

PMID:
25188468
5.

Examining the relationship between pre- and postimplant geometry in prostate low-dose-rate brachytherapy and its correlation with dosimetric quality using the similarity concept.

Todor DA, Anscher MS, Karlin JD, Hagan MP.

Brachytherapy. 2014 Sep-Oct;13(5):471-80. doi: 10.1016/j.brachy.2014.06.002. Epub 2014 Jul 15. Erratum in: Brachytherapy. 2014 Nov-Dec;13(6):671. Karlin, Jeremy D [added].

PMID:
25037911
6.

Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.

Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A.

Oncologist. 2013 Jun;18(6):685-6. doi: 10.1634/theoncologist.2012-0461. Epub 2013 May 31.

7.

Identifying appropriate patients for early salvage radiotherapy after prostatectomy.

Karlin JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, Wan W, Hagan MP, Anscher MS, Moghanaki D.

J Urol. 2013 Oct;190(4):1410-5. doi: 10.1016/j.juro.2013.04.078. Epub 2013 May 3.

PMID:
23648223
8.

The effect of a cognitive treatment program for male and female juvenile offenders.

McGlynn AH, Hahn P, Hagan MP.

Int J Offender Ther Comp Criminol. 2013 Sep;57(9):1107-19. doi: 10.1177/0306624X12463341. Epub 2012 Nov 2.

PMID:
23123384
9.

Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy.

Moghanaki D, Koontz BF, Karlin JD, Wan W, Mukhopadhay N, Hagan MP, Anscher MS.

Cancer. 2013 Jan 1;119(1):52-60. doi: 10.1002/cncr.27712. Epub 2012 Jun 26.

10.

Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.

Myers MA, Hagan MP, Todor D, Gilbert L, Mukhopadhyay N, Randolf J, Heimiller J, Anscher MS.

Brachytherapy. 2012 Jul-Aug;11(4):292-8. doi: 10.1016/j.brachy.2011.07.006. Epub 2012 Mar 30.

PMID:
22464911
11.

Factors associated with program utilization of radiation therapy treatment for VHA and medicare dually enrolled patients.

French DD, Bradham DD, Campbell RR, Haggstrom DA, Myers LJ, Chumbler NR, Hagan MP.

J Community Health. 2012 Aug;37(4):882-7. doi: 10.1007/s10900-011-9523-y.

PMID:
22139021
12.

Regulatory evaluation of prostate volume implants: pitfalls of a retrospective assessment.

Hagan MP, Saleh H, Moore M, Williamson J.

Brachytherapy. 2011 Sep-Oct;10(5):385-94. doi: 10.1016/j.brachy.2011.01.005. Epub 2011 Feb 24.

PMID:
21349777
13.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM.

J Clin Oncol. 2009 Sep 1;27(25):4055-61. doi: 10.1200/JCO.2008.19.5776. Epub 2009 Jul 27.

14.

Monte Carlo dose verification of prostate patients treated with simultaneous integrated boost intensity modulated radiation therapy.

Dogan N, Mihaylov I, Wu Y, Keall PJ, Siebers JV, Hagan MP.

Radiat Oncol. 2009 Jun 15;4:18. doi: 10.1186/1748-717X-4-18.

15.

Evaluation of a cognitive intervention program for juvenile offenders.

Bogestad AJ, Kettler RJ, Hagan MP.

Int J Offender Ther Comp Criminol. 2010 Aug;54(4):552-65. doi: 10.1177/0306624X09337211. Epub 2009 Jun 3.

PMID:
19494167
16.

Five-year accuracy of assessments of high risk for sexual recidivism of adolescents.

Hagan MP, Anderson DL, Caldwell MS, Kemper TS.

Int J Offender Ther Comp Criminol. 2010 Feb;54(1):61-70. doi: 10.1177/0306624X08325348. Epub 2008 Oct 28.

PMID:
18957553
17.

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P.

Mol Cancer Ther. 2008 Sep;7(9):2633-48. doi: 10.1158/1535-7163.MCT-08-0400.

18.

Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.

Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P.

Mol Pharmacol. 2008 Sep;74(3):807-22. doi: 10.1124/mol.108.047365. Epub 2008 Jun 10.

19.

Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.

Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P.

Cancer Biol Ther. 2008 Apr;7(4):587-93. Epub 2008 Jan 8.

PMID:
18379195
20.

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.

Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P.

Mol Cancer Ther. 2008 Mar;7(3):616-29. doi: 10.1158/1535-7163.MCT-07-2376.

21.

OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.

Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, Dent P.

Mol Pharmacol. 2008 Apr;73(4):1168-84. doi: 10.1124/mol.107.042697. Epub 2008 Jan 8.

22.

A strategy to correct for intrafraction target translation in conformal prostate radiotherapy: simulation results.

Keall PJ, Lauve AD, Hagan MP, Siebers JV.

Med Phys. 2007 Jun;34(6):1944-51.

PMID:
17654897
23.

Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling.

Mitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P.

Mol Pharmacol. 2007 Sep;72(3):704-14. Epub 2007 Jun 19.

PMID:
17578896
24.

Radiation-induced cell signaling: inside-out and outside-in.

Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P.

Mol Cancer Ther. 2007 Mar;6(3):789-801. Review.

25.

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP.

Urol Oncol. 2007 Mar-Apr;25(2):101-9.

PMID:
17349523
26.

Radiation-induced PARP activation is enhanced through EGFR-ERK signaling.

Hagan MP, Yacoub A, Dent P.

J Cell Biochem. 2007 Aug 15;101(6):1384-93.

PMID:
17295209
27.

Radiotherapy-induced signal transduction.

Yacoub A, Miller A, Caron RW, Qiao L, Curiel DA, Fisher PB, Hagan MP, Grant S, Dent P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S99-114.

PMID:
17259563
28.

Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.

Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P.

Mol Pharmacol. 2007 Jan;71(1):259-75. Epub 2006 Oct 18. Erratum in: Mol Pharmacol. 2016 Aug;90(2):151-2.

PMID:
17050804
29.

MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.

Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P.

Cancer Biol Ther. 2006 Oct;5(10):1332-9. Epub 2006 Oct 15.

PMID:
16957420
30.

A dynamic compensation strategy to correct patient-positioning errors in conformal prostate radiotherapy.

Lauve AD, Siebers JV, Crimaldi AJ, Hagan MP, Kealla PJ.

Med Phys. 2006 Jun;33(6):1879-87.

PMID:
16872095
31.

Screening for suicide among juvenile delinquents: reliability and validity evidence for the Suicide Screening Inventory (SSI).

Kaczmarek TL, Hagan MP, Kettler RJ.

Int J Offender Ther Comp Criminol. 2006 Apr;50(2):204-17.

PMID:
16510890
32.

Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.

Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, Grant S, Dent P.

Mol Cancer Ther. 2005 Feb;4(2):257-70.

33.

H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.

Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P.

Mol Cancer Ther. 2005 Feb;4(2):243-55.

34.

Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells.

Carón RW, Yacoub A, Mitchell C, Zhu X, Hong Y, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P.

Cell Cycle. 2005 Mar;4(3):456-64. Epub 2005 Mar 28.

PMID:
15655348
35.

RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72.

PMID:
14529770
36.

MAPK pathways in radiation responses.

Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S.

Oncogene. 2003 Sep 1;22(37):5885-96. Review.

PMID:
12947395
37.
38.

Stress and radiation-induced activation of multiple intracellular signaling pathways.

Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R.

Radiat Res. 2003 Mar;159(3):283-300. Review.

PMID:
12600231
39.

Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.

McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P.

Cancer Biol Ther. 2002 May-Jun;1(3):243-53.

PMID:
12432271
40.

Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.

Qiao L, Yacoub A, McKinstry R, Park JS, Caron R, Fisher PB, Hagan MP, Grant S, Dent P.

Cancer Biol Ther. 2002 Mar-Apr;1(2):168-76.

PMID:
12170777
41.

Autocrine loops with positive feedback enable context-dependent cell signaling.

Shvartsman SY, Hagan MP, Yacoub A, Dent P, Wiley HS, Lauffenburger DA.

Am J Physiol Cell Physiol. 2002 Mar;282(3):C545-59.

43.

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways.

Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P.

Oncogene. 2001 May 31;20(25):3266-80. Erratum in: Oncogene 2001 Nov 22;20(53):7817.

44.

Superior sulcus lung tumors: impact of local control on survival.

Hagan MP, Choi NC, Mathisen DJ, Wain JC, Wright CD, Grillo HC.

J Thorac Cardiovasc Surg. 1999 Jun;117(6):1086-94.

45.

Caffeine-induced apoptosis reveals a persistent lesion after treatment with bromodeoxyuridine and ultraviolet-B light.

Hagan MP, Hopcia KL, Sylvester FC, Held KD.

Radiat Res. 1997 Jun;147(6):674-9.

PMID:
9189164
46.

Tumor proliferation in rectal cancer following preoperative irradiation.

Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC, Compton CC.

J Clin Oncol. 1995 Jun;13(6):1417-24.

PMID:
7751887
47.

Impaired repair of UVC-induced DNA damage in L5178Y-R cells: sedimentation studies with the use of 5'-bromodeoxyuridine photolysis.

Hagan MP, Dodgen DP, Beer JZ.

Photochem Photobiol. 1988 Jun;47(6):815-21. No abstract available.

PMID:
3217433
48.
49.

Effects of heavy ions on cycling stem cells.

Hagan MP, Holahan EV, Ainsworth EJ.

Adv Space Res. 1986;6(11):201-11.

PMID:
11537222
50.

Cell kinetics of GM-CFC in the steady state.

Hagan MP, MacVittie TJ, Dodgen DP.

Exp Hematol. 1985 Jul;13(6):532-8.

PMID:
3996490

Supplemental Content

Loading ...
Support Center